Meeting Abstract: 352
Sonia Brun(Genoscience Pharma (France)), Philippe Halfon(Genoscience Pharma (France)), Éric Raymond(Hôpital Paris Saint-Joseph), Philippe Fabre(Sanofi (France)), Christelle Ansaldi(Genoscience Pharma (France)), Firas Bassissi(Genoscience Pharma (France)), Marie Guillemot(Evotec (United States)), Marie Novello(Genoscience Pharma (France)), Cindy Serdjebi(Genoscience Pharma (France)), Jennifer Tracz(Genoscience Pharma (France)), Jérôme Courcambeck(Genoscience Pharma (France)), Madani Rachid, François Autelitano(Evotec (Germany))
HAL (Le Centre pour la Communication Scientifique Directe)
November 1, 2019
Cited by 0
Related Papers
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|Annals of Oncology|2015|698
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
|Journal of Clinical Oncology|2008|226
SAFE biopsy
|Hepatology|2009|183
Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study
|Journal of Hepatology|2010|151
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
|Journal of Viral Hepatitis|2005|143